Enabling you to identify and mitigate the intrinsic risk in your operations, supply chains and business processes.
Evaluating how your products and services meet and exceed quality, safety, sustainability and performance standards.
Validating the specifications, value and safety of your raw materials, products and assets.
Cambridge, United Kingdom – Intertek, a leading global Total Quality Assurance provider to industries worldwide, today announced that Intertek’s Technical Director for Inhalation Product Development will conduct a workshop on inhalation and nasal drug products for scientists from the pharmaceutical industry, during the RDD Asia conference, Goa, India, November 8-11, 2016.
The Intertek workshop will cover the specific studies required to characterise the performance properties of nasal spray and inhalation solution, suspension, and spray drug products, and the required labelling statements regarding use, such as storage, cleaning and shaking.
Inhalation delivery systems for drug products can vary in both design and mode of operation, and these characteristics may be unique to a particular drug product. Studies to define these characteristics help facilitate correct use and maintenance of the drug product and contribute to patient compliance. During RDD Asia, Mark Parry, Intertek’s Technical Director, will provide industry professionals with strategic approaches to product characterisation studies to generate the data required to complete key marketing documents such as the summary of products characterisation (SmPC) and the patient information leaflet (PIL).
Mark Parry Technical Director, Intertek Melbourn shared “During our RDD Asia workshop we will walk participants through the vital key product characterisation studies for inhalation and nasal drug products all the way from chemical, physicochemical, and performance testing to stability dossiers allowing for successful regulatory submission of OINDPs”. Intertek’s integrated formulation and analytical teams have over 20 year of experience in conducting early stage pre-formulation support, solubility screening, drug-excipient compatibility, stability testing and device selection support, so are well placed to help clients working to develop formulations targeting specific regions of the respiratory tract or nasal cavity,” he added.
RDD Asia offers attendees the opportunity to participate in one of the largest and most focussed international conferences on respiratory drug delivery in Asia. It will feature industry updates, in-depth presentations and discussion of pioneering respiratory drug delivery science relating to pMDIs, DPIs, nebulizers, nasal sprays and emerging aerosol delivery platforms.
Intertek is a leading Total Quality Assurance provider to industries worldwide. Our network of more than 1,000 laboratories and offices and over 40,000 people in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers’ operations and supply chains.
Bringing quality and safety to life
Dr Lorna Kettle
Marketing Manager, Intertek Pharmaceutical Services, Europe
Tel.:+44 161 721 1476
Intertek RDD Asia Workshop:
Product Characterisation Studies: What are they, why are they done, and what is involved?
Date: November 9th 2016, 2:00 PM – 5:00 PM